Humanigen Inc

Humanigen — Corporate Update (September 2021)

24 slides from Humanigen's corporate update, Sep 14, 2021

  1. Slide 1: Humanigen September 2021

    Humanigen September 2021 Humanigen

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    2 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this presentation are forward - loo

  3. Slide 3: Company Overview

    3 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Company Overview Leading expertise in Hyper - inflammation and Cytokine Storm across multiple therapeutic applications Filed for for Conditional Marketing Autho

  4. Slide 4: Business Update: September 2021

    4 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Business Update: September 2021 Lenzilumab for COVID - 19 • September 8, 2021 FDA response to EUA submission: • Declined EUA at this time - invited Humanigen to

  5. Slide 5: Robust Clinical Pipeline

    5 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Robust Clinical Pipeline Indication Phase Status Centers Partners Lenzilumab LIVE - AIR Hospitalized COVID - 19 3 Completed (520 patients) 24 US 11 Brazil Compa

  6. Slide 6: LIVE-AIR Demographics and Baseline Characteristics (mITT Population)

    6 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry LIVE - AIR Demographics and Baseline Characteristics ( mITT Population) Characteristics Lenzilumab (N=236) Placebo (N=243) Overall (N=479) Age Mean (SD) 60.5 (1

  7. Slide 7: Study Primary Endpoint Met

    7 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Study Primary Endpoint Met Kaplan - Meier Estimates For IMV and/or Death Failure to achieve survival without ventilation was defined as mortality or the require

  8. Slide 8: Patients With Baseline CRP<150 mg/L Required IMV Or Died Less

    8 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Patients With Baseline CRP<150 mg/L Required IMV Or Died *Study was not powered to demonstrate a difference in mortality 4.0 29.3 0 10 20 30 40 Lenzilumab Place

  9. Slide 9: Safety Balanced Between Treatment Arms

    9 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Safety Balanced Between Treatment Arms System Organ Class Preferred Term n (%) Lenzilumab (N=255) Placebo (N=257) Overall (N=512) Any AE ≥ Grade 3 68 (26.7) 84

  10. Slide 10: Cardiac SAEs from LIVE-AIR

    10 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Cardiac SAEs from LIVE - AIR Preferred Term n (%) Lenzilumab (N=255) Placebo (N=257) Overall (N=512) All cardiac SAEs 12 (4.7) 13 (5.1) 25 (4.9) Cardiac arrest

  11. Slide 11: US Hospitalization Rates Continue at Accelerating Pace

    11 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry US Hospitalization Rates Continue at Accelerating Pace (>100,000*) *As of September 2021 Sources: https://covid.cdc.gov/covid - data - tracker/?CDC_AA_refVal=h

  12. Slide 12: Lenzilumab in the United Kingdom

    Lenzilumab in the United Kingdom

  13. Slide 13: Multiple Agency Interactions

    13 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Multiple Agency Interactions x Introductory meeting held with Rapid C - 19 multi - agencies (MHRA, Therapeutics Task Force (TTF), NICE, NHSE, DHSC) x MAA accep

  14. Slide 14: Cases Continue to Rise Despite High Vaccination Rate

    14 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Cases Continue to Rise Despite High Vaccination Rate (Currently 65%) * https://www.pharmaceutical - technology.com/covid - 19 - vaccination - tracker/ https://

  15. Slide 15: Key UK Statistics

    15 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Key UK Statistics (as of September 12, 2021) • >134,000 deaths • Daily death rate 30% vs. September 5 • 30,000 people tested positive September 11 • 7.2 millio

  16. Slide 16: UK Commercial Preparation

    16 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry UK Commercial Preparation UK launch plan developed in parallel with US preparation and leverages multiple tools already created in anticipation of US launch •

  17. Slide 17: Clinical Development Pipeline

    Clinical Development Pipeline

  18. Slide 18: ZUMA-19 Phase 1b Results

    18 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry ZUMA - 19 Phase 1b Results • Lenzilumab in combination with CAR - T in DLBCL demonstrated a 100% objective response rate (ORR) at the recommended Phase 2 dose

  19. Slide 19: Significant CAR-T Market Growth Expected

    19 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Significant CAR - T Market Growth Expected DLBCL patients receiving commercial CAR - T Therapy Lenzilumab + CAR - T CAR - T Primary outcome : Efficacy and Toxi

  20. Slide 20: Acute Graft vs. Host Disease (aGvHD): Growing Market, High Unmet Need

    20 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Acute Graft vs. Host Disease ( aGvHD ): Growing Market, High Unmet Need Steroids used for initial treatment of aGvHD 2 - 6 ~50% of patients do not respond adeq

  21. Slide 21: PREACH-M trial (PREcision Approach to CHronic Myelomonocytic Leukemia)

    21 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry PREACH – M trial ( PREcision Approach to CHronic Myelomonocytic Leukemia) CMML is an aggressive Cancer 1 12.8 cases/100,000 persons per year 2 Incidence higher

  22. Slide 22: Ifabotuzumab Data in GBM and Development Plan

    22 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry MRI ( T1 + C) 89 Zr - ifabotuzumab PET 18 F - FDG PET Phase 1 study: multiple tumors Breast Lung Colorectal Pancreas No normal tissue uptake of 89 Zr - ifabotu

  23. Slide 23: Financial Overview

    23 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Financial Overview Balance (based on 10 - Q filing as of June 30, 2021) • Cash and cash equivalents $120MM • Q2 manufacturing scale - up, advance purchasing of

  24. Slide 24: Month Goals

    24 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry 12 Month Goals □ Complete regulatory submission for lenzilumab in hospitalized COVID - 19 in the UK in September and commence commercialization if authorized □

Humanigen — Corporate Update (September 2021) on 6ix